eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference

The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…

Retinal Ischemia Tied to Variant of Acute Macular Neuroretinopathy

Paracentral acute middle maculopathy is a newly identified variant of acute macular neuroretinopathy that appears to result from retinal capillary ischemia, according to a retrospective observational case series. “This has been traditionally a very rare disease but now with advanced retinal imaging systems such as spectral domain optical coherence tomography (SD-OCT) and infrared reflectance imaging…

First successful transplant of retinas made from embryonic stem cells

For the first time, scientists have successfully transplanted light-detecting cells in the retina, grown from embryonic stem cells, into mice–a feat that could advance similar therapies using the artificial cells to treat degenerative eye diseases toward human trials. The animal transplant is a huge step for embryonic stem cell-based therapies, which have moved slowly to…

Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments

Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing.  Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications.   eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…

Calvert Labs and eyecro Announce Strategic Partnership in Ocular Research

Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities.  “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…

iPad Vision Test Big Hit With Macular Degeneration Patients

An overwhelming majority of people with age-related macular degeneration would rather test their vision with an iPad app than with traditional methods, a new study shows. “One of the major advantages of iPad testing is that patients are much more involved in their disease. They’re engaged,” Matthias Hartmann, MD, an ophthalmologist in private practice from…

Diabetic Retinopathy, Microalbuminuria Predict GFR Decline

Having diabetic retinopathy and/or microalbuminuria predicted a much higher rate of annual decline in glomerular filtration rate (GFR) in a new study of patients with type 2 diabetes living in Japan. Diabetic retinopathy is a known risk factor for microalbuminuria, and microalbuminuria is a risk factor for macroalbuminuria, but to date it has been unclear…

AMD-Risk Genes: Global Collaborative Finds 7 New Sites

An international research collaborative has identified 7 new genetic loci associated with an increased risk of developing age-related macular degeneration (AMD), bringing the total number of known AMD-susceptibility loci in the human genome to 19. Scientists from 18 research groups in 14 countries formed the consortium in the spring of 2010 with the goal of…